Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase IIa clinical trials for the treatment of ulcerative colitis and atopic dermatitis. The company also develops value-added products for dermo-cosmetics, and distributes pharmaceutical products. In addition, it acquires drug and health product licenses. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2013 and is headquartered in Québec, Canada.